MRNA - Moderna, Inc.
The recent meteoric rally of MRNA shares has made Moderna a massive company. Its market cap has grown so large, in fact, that it's earned a place among Nasdaq's largest listings.
A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig, BioNTech's oncology pipeline is moving well beyond early-stage research.
Momentum is only half the battle. Their underlying companies still need to justify the continued bullishness of their stocks.
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the biotechnology to its 52-week high. The shares, which reached $242.29 during their recent advance, were trading near $213 at the time of writing.
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.
The Dow and Nasdaq are once more moving in opposite directions, as investors flee AI stocks
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.
AI stocks have been known for explosive gains in recent years and have driven the S&P 500 higher. This year, some investors scored a much bigger win by investing in a promising biotech stock.
Moderna has staged a dramatic rebound, becoming the best-performing S&P 500 stock YTD, driven by pipeline optimism and strong technical momentum. I maintain a "Hold" rating on MRNA due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Key catalysts include upcoming Q3 earnings on November 6 and Analyst Day on November 12, with high implied volatility and significant event-driven price risk.
Shares of Nike Inc. (NYSE:NKE), Moderna Inc. (NASDAQ:MRNA) and Walmart Inc. (NASDAQ:WMT) climbed Thursday as money flowed out of tech and AI stocks for a second straight session.
Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.
Noubar Afeyan, Co-Founder & Chairman, Moderna and Founder & CEO, Flagship Pioneering; Lila Ibrahim, Chief AI Readiness Officer, Google DeepMind; and Kiran Mazumdar-Shaw, Founder & Executive Chairperson, Biocon discuss how AI is reshaping scientific discovery with Bloomberg's Francine Lacqua at the 2026 Bloomberg New Economy Forum in New Delhi. -------- More on Bloomberg Television and Markets Like this video?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.
Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex system," but said Merck and Moderna have the process "down to a very tight science.
Shares of Moderna MRNA have gained more than 5% over the past week, adding roughly $4.2 billion in market value.
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
Moderna is leveraging its mRNA platform to expand beyond COVID-19 vaccines into RSV and oncology therapeutics. Vertex Pharmaceuticals maintains market dominance in cystic fibrosis while successfully diversifying into gene therapy and pain management.
CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third quarter 2026 financial results, and provide a corporate update.
In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.